Zentalis Pharmaceuticals, INC. (ZNTL) — 10-Q Filings

10-Q Filings (6)

• Zentalis Narrows Q3 Loss Amidst R&D Cuts, Cash Position Improves — Nov 10, 2025 Risk: high
  Zentalis Pharmaceuticals, Inc. (ZNTL) reported a net loss of $26.691 million for the three months ended September 30, 2025, a decrease from the $40.158 million
• Zentalis Reports No Revenue, Focuses on Clinical Pipeline Advancement — Aug 6, 2025 Risk: high
  Zentalis Pharmaceuticals, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with the prior year periods, as it remains a cli
• Zentalis Pharmaceuticals Files Q1 2025 10-Q — May 14, 2025 Risk: medium
  Zentalis Pharmaceuticals, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported its financial results and provided updates on its busin
• Zentalis Pharmaceuticals Files Q3 2024 10-Q — Nov 12, 2024 Risk: medium
  Zentalis Pharmaceuticals, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported its financial results and provided updates on its b
• Zentalis Pharmaceuticals Files Q2 2024 10-Q — Aug 9, 2024 Risk: medium
  Zentalis Pharmaceuticals, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and provided updates on its busine
• Zentalis Pharmaceuticals, Inc. Files 10-Q for Period Ending March 31, 2024 — May 7, 2024 Risk: low
  Zentalis Pharmaceuticals, Inc. (ZNTL) filed a Quarterly Report (10-Q) with the SEC on May 7, 2024. Zentalis Pharmaceuticals, Inc. filed a 10-Q report for the pe

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX